Terms: = Lung cancer AND DDR2, NTRKR3, 4921, ENSG00000162733, Q16832, MIG20a, TYRO10 AND Treatment
35 results:
1. Genetic determinants of lung cancer: Understanding the oncogenic potential of somatic missense mutations.
Dhakar R; Dakal TC; Sharma A
Genomics; 2022 Jul; 114(4):110401. PubMed ID: 35709927
[TBL] [Abstract] [Full Text] [Related]
2. Tyrosine kinase-independent actions of ddr2 in tumor cells and cancer-associated fibroblasts influence tumor invasion, migration and metastasis.
Barcus CE; Hwang PY; Morikis V; Brenot A; Pence P; Clarke M; Longmore GD
J Cell Sci; 2021 Oct; 134(19):. PubMed ID: 34477203
[TBL] [Abstract] [Full Text] [Related]
3. An Epithelial-to-Mesenchymal Transcriptional Switch Triggers Evolution of Pulmonary Sarcomatoid Carcinoma (PSC) and Identifies Dasatinib as New Therapeutic Option.
Manzotti G; Torricelli F; Benedetta D; Lococo F; Sancisi V; Rossi G; Piana S; Ciarrocchi A
Clin Cancer Res; 2019 Apr; 25(7):2348-2360. PubMed ID: 30587547
[TBL] [Abstract] [Full Text] [Related]
4. Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma.
Wang Q; Dai Y; Ji Y; Shi H; Guo Z; Chen D; Chen Y; Peng X; Gao Y; Wang X; Chen L; Jiang Y; Geng M; Shen J; Ai J; Xiong B
Eur J Med Chem; 2019 Feb; 163():671-689. PubMed ID: 30572178
[TBL] [Abstract] [Full Text] [Related]
5. Distribution of KRAS, ddr2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
[TBL] [Abstract] [Full Text] [Related]
6. Targeted therapy in nonsmall cell lung cancer.
Puri T
Indian J Cancer; 2017; 54(1):83-88. PubMed ID: 29199670
[TBL] [Abstract] [Full Text] [Related]
7. Molecular Adequacy of Image-Guided Rebiopsies for Molecular Retesting in Advanced Non-Small Cell lung cancer: A Single-Center Experience.
Tokaca N; Barth S; O'Brien M; Bhosle J; Fotiadis N; Wotherspoon A; Thompson L; Popat S
J Thorac Oncol; 2018 Jan; 13(1):63-72. PubMed ID: 28989040
[TBL] [Abstract] [Full Text] [Related]
8. Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the treatment of Non-Small Cell lung cancer.
Zhu W; Chen H; Wang Y; Wang J; Peng X; Chen X; Gao Y; Li C; He Y; Ai J; Geng M; Zheng M; Liu H
J Med Chem; 2017 Jul; 60(14):6018-6035. PubMed ID: 28714692
[TBL] [Abstract] [Full Text] [Related]
9. Functional analysis of Discoidin domain receptor 2 mutation and expression in squamous cell lung cancer.
Kobayashi-Watanabe N; Sato A; Watanabe T; Abe T; Nakashima C; Sueoka E; Kimura S; Sueoka-Aragane N
Lung Cancer; 2017 Aug; 110():35-41. PubMed ID: 28676216
[TBL] [Abstract] [Full Text] [Related]
10. Presence of cancer-associated mutations in exhaled breath condensates of healthy individuals by next generation sequencing.
Youssef O; Knuuttila A; Piirilä P; Böhling T; Sarhadi V; Knuutila S
Oncotarget; 2017 Mar; 8(11):18166-18176. PubMed ID: 28199989
[TBL] [Abstract] [Full Text] [Related]
11. Targeting of Discoidin Domain Receptor 2 (ddr2) Prevents Myofibroblast Activation and Neovessel Formation During Pulmonary Fibrosis.
Zhao H; Bian H; Bu X; Zhang S; Zhang P; Yu J; Lai X; Li D; Zhu C; Yao L; Su J
Mol Ther; 2016 Oct; 24(10):1734-1744. PubMed ID: 27350126
[TBL] [Abstract] [Full Text] [Related]
12. Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean lung cancer Consortium).
Lim SM; Kim HR; Cho EK; Min YJ; Ahn JS; Ahn MJ; Park K; Cho BC; Lee JH; Jeong HC; Kim EK; Kim JH
Oncotarget; 2016 Jun; 7(24):36311-36320. PubMed ID: 27121209
[TBL] [Abstract] [Full Text] [Related]
13. Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell lung cancer: Double-Edged Sword of ddr2.
Terashima M; Togashi Y; Sato K; Mizuuchi H; Sakai K; Suda K; Nakamura Y; Banno E; Hayashi H; De Velasco MA; Fujita Y; Tomida S; Mitsudomi T; Nishio K
Clin Cancer Res; 2016 Jul; 22(14):3663-71. PubMed ID: 26826182
[TBL] [Abstract] [Full Text] [Related]
14. Mutation Profiling of lung cancers with Long-Term Response to Gefitinib Therapy.
Gautschi O; Stadelmann C; Aebersold-Keller F; König K; Büttner R; Heukamp LC; Betticher D; Baumann C; Buser K; Calderoni A; Casty A; DʼAddario G; Irlé C; Mamot C; Morant R; Trojan A; Pellicioli E; Jehle-Schwertfeger S; Aebi S; Diebold J
Oncol Res Treat; 2015; 38(11):560-9. PubMed ID: 26599269
[TBL] [Abstract] [Full Text] [Related]
15. Characterization of ddr2 Inhibitors for the treatment of ddr2 Mutated Nonsmall Cell lung cancer.
Terai H; Tan L; Beauchamp EM; Hatcher JM; Liu Q; Meyerson M; Gray NS; Hammerman PS
ACS Chem Biol; 2015 Dec; 10(12):2687-96. PubMed ID: 26390252
[TBL] [Abstract] [Full Text] [Related]
16. NSCLC Driven by ddr2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy.
Xu C; Buczkowski KA; Zhang Y; Asahina H; Beauchamp EM; Terai H; Li YY; Meyerson M; Wong KK; Hammerman PS
Mol Cancer Ther; 2015 Oct; 14(10):2382-2389. PubMed ID: 26206333
[TBL] [Abstract] [Full Text] [Related]
17. Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of lung cancer Patients.
König K; Peifer M; Fassunke J; Ihle MA; Künstlinger H; Heydt C; Stamm K; Ueckeroth F; Vollbrecht C; Bos M; Gardizi M; Scheffler M; Nogova L; Leenders F; Albus K; Meder L; Becker K; Florin A; Rommerscheidt-Fuss U; Altmüller J; Kloth M; Nürnberg P; Henkel T; Bikár SE; Sos ML; Geese WJ; Strauss L; Ko YD; Gerigk U; Odenthal M; Zander T; Wolf J; Merkelbach-Bruse S; Buettner R; Heukamp LC
J Thorac Oncol; 2015 Jul; 10(7):1049-57. PubMed ID: 26102443
[TBL] [Abstract] [Full Text] [Related]
18. Inhibition of discoidin domain receptor 2-mediated lung cancer cells progression by gold nanoparticle-aptamer-assisted delivery of peptides containing transmembrane-juxtamembrane 1/2 domain.
Kim D; Yeom JH; Lee B; Lee K; Bae J; Rhee S
Biochem Biophys Res Commun; 2015 Aug; 464(2):392-5. PubMed ID: 26067556
[TBL] [Abstract] [Full Text] [Related]
19. Beyond adenocarcinoma: current treatments and future directions for squamous, small cell, and rare lung cancer histologies.
Gerber DE; Paik PK; Dowlati A
Am Soc Clin Oncol Educ Book; 2015; ():147-62. PubMed ID: 25993153
[TBL] [Abstract] [Full Text] [Related]
20. Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer.
Nicoś M; Krawczyk P; Jarosz B; Sawicki M; Szumiłło J; Trojanowski T; Milanowski J
Clin Exp Med; 2016 May; 16(2):169-76. PubMed ID: 25902737
[TBL] [Abstract] [Full Text] [Related]
[Next]
